Specialty biologics are the fastest growing class of bio/pharmaceutical products in terms of the number of new brand launches and rates of health care spending in the U.S. and globally. Innovative biologics meant to treat a range of hitherto untreatable conditions in oncology, inflammation, CNS, endocrinology and other chronic conditions seek to offer radical improvements in efficacy and patient well-being. Such products can command premium prices, often costing over $100K per year per patient - triggering a raft of challenges to ensuring that eligible patients have adequate access.
Â This article outlines important trends impacting market access to specialty biologics in the U.S. and globally. Particular importance is placed on evolving methods for managing specialty product utilization and reimbursement toward ensuring appropriate access. The reshaping of the specialty product market access landscape in the U.S. through the availability of oral biologic formulations distributed to patients via high-touch, high-involvement specialty pharmacies is examined. The rising role of risk sharing between specialty product manufacturers and insurers as a way to balance rewards of access with the risks inherent in radical new specialty therapeutics is discussed. Challenges posed by specialty biosimilars to traditional ways of ensuring market access and fair reimbursement are outlined. The impact of health care reforms on market access for specialty biologics in the U.S. is discussed in the context of the growing need for comparative outcomes research and the application of the principles of health technology assessments - adapted, in part from their apparent success in ensuring equitable and cost-effective access to biologics in the E.U.
EMD Serono. EMD Serono Specialty Digest, 7th Edition. 2011
Bach, B. Peter, Lenoard B. Saltz & Robert E. Wittes, â€˜In Cancer Care, Cost Mattersâ€™, The Opinion Pages, The New York Times, October 14, 2012
Morgan, Sarah, â€˜Specialty Pharma Coverage At The Crossroadsâ€™, Medical Marketing & Media, March 1, 2014
Rao, Sanjay K., â€˜PM360 Feature: Strategic Priorities For Specialty Care Productsâ€™, PM360, August 2011
Medical Pharmacy & Oncology Trend Report; Magellan Pharmacy Solutions & Icore Healthcare, 2012
The 2013 Genentech Oncology Trend Report, Genentech
The Community Oncology Practice Impact Report & Update; Community Oncology Alliance, April, 2012 & June 2013
Total Cost of Cancer Care by Site of Service: Physician Office vs. Outpatient Hospital. Avalere Health, May, 2012; & Site of Service Cost Differences for Medicare Patients Receiving Chemotherapy. Milliman, October, 2011.
Barlas, Stephen, â€˜Federal Investigative Report Questions 340B Contract Pharmacy Programs; Office of Pharmacy Affairs Promises Regulatory Responseâ€™; P&T Magazine, v39, No.4, April 2014
D. Guy & Rodgers, S., â€˜Most Cancer Patients Will Be Treated in Integrated Delivery Networks (IDN) and Cancer Institutions by 2016, Predicts New Reportâ€™, Inside Oncology, August 15, 2012.
Mullen, Patrick, â€˜The Arrival of ASPâ€™; Biotechnology Healthcare, June 2007; & Bradbury, Keith, â€˜Specialty Drugs â€“ Rich Pipeline That Needs To Be Managedâ€™; Biotechnology Healthcare, Oct/Nov. 2009
Holcombe, Dawn G.,â€™Is oncology compatible with specialty pharmacy?â€™ Community Oncology, March-April 2005
Rao, Sanjay K., â€˜Pricing Biologics : Issues, strategic priorities and a conceptual modelâ€™, Journal of Commercial Biotechnology, v17, I, 7-23, 2011
Carlson, Josh, Louis P. Garrison, Sean D. Sullivan; â€˜Paying for outcomes: innovative coverage & reimbursement schemes for pharmaceuticalsâ€™; Journal of Managed Care Pharmacy, v15, # 8, 2009
Garrison, Louis P et al, â€˜Performance-based risk-sharing arrangements-Good practices for design, implementation, and evaluation: report of the ISPOR task forceâ€™; Value In Health, v16, 703-719; 2013
EMD Serono. EMD Serono Specialty Digest, 8th Edition. 2012
Trosman et al. , â€˜Health Technology Assessment and Private Payersâ€™ Coverage of Personalized Medicine, Journal of Oncology Practiceâ€™, Vol. 7, May 2011 (3 Suppl) & Mullins C. Daniels et al, â€˜How Do U.S. Healthcare Payers React To & Use Pharmcoeconomic Information?â€™ International Journal of the Economics of Business, , v18, No. 2, 2011
Barnes, Lauren et al, â€˜Oral Oncolytics / Addressing the Barriers to Access & Identifying Areas for Engagementâ€™, Avalere, supported by funds from the Community Oncology Alliance, 2010
Pollack, Andrew, â€˜Gov. Brown of California Vetoes Biotech Drug Billâ€™, New York Times, October 13, 2013
The OPTUM ACO survey of 1000 MDs and 400 Hospital Executives (June 2012); & Murphy, Kyle â€˜ACOs doubled during past year, Medicare outpaced commercialâ€™, EHR Intelligence, 2013
See http: //pha.purdue.edu/news/survey; â€˜Survey reveals hospital executives reluctant to implement ACO modelsâ€™; Purdue Healthcare Advisors, Dec. 20, 2013
Unless specified by prior arrangement, the author agrees to the following terms and assurances:
- For myself and on behalf of the other authors listed on this work, I assign to thinkBiotech LLC the copyright* in the contribution for the full term throughout the world.
- I/we further give to the following assurances
- I am the sole author of the contribution, or, if not, I have the written authority of the other authors to transfer the copyright* to thinkBiotech LLC and give these warranties;
- I and (where appropriate) the other authors are entitled to transfer the copyright to thinkBiotech LLC and no one else would be entitled to prevent us from publishing the contribution;
- To the best of my/our knowledge, all the facts in the contribution are true and accurate;
- The content of the contribution is entirely original to me (and where appropriate to the other authors) or, if not, the written permission of the owner of the copyright in any material copied from elsewhere has been obtained for all media (all such permissions to be attached to the contribution as supplementary files);
- Nothing in the contribution is obscene or libellous;
- Nothing in the contribution infringes any duty of confidentiality which I/or the other authors may owe to anyone else.
- I and/or the other authors have obtained the appropriate clearances from my/our employer(s) or other concerned institution(s).